Lymphoma, Cutaneous T-cell (CTCL)
Pathogenesis and Course of Cutaneous T-Cell Lymphoma
NCI-04-C-0081
Print this page 
Investigator(s): |
Sam Hwang, M.D.
Principal Investigator
Phone: 301-496-8724
hwangs@mail.nih.gov
|
|
|
|
Susan Booher, M.S., R.N.
Research Nurse
Phone: 301-402-1474
boohers@mail.nih.gov
|
|
|
| |
Primary Eligibility:
- Confirmed diagnosis of cutaneous T-cell lymphoma (mycosis fungoides or Sezary syndrome) stage IA to IVB; other primary or secondary cutaneous T-cell lymphoma confirmed by clinical and histologic examination
- A pre-CTCL skin condition, including large plaque parapsoriasis and lymphomatoid papulosis, confirmed by clinical and histologic examination
- Patients must have disease that is measurable by assessment of skin lesions or quantification of Sezary cell count
- Patients must be 18 years of age
- Must be referred from a physician who will continue their care and treatment in tandem with the protocol
Treatment Plan:
- Confirmation of diagnosis will be made from analysis of previous skin or lymph node biopsies or from tissue obtained at time of screening
- Patients will have physical examination, blood tests, skin lesion biopsies, photographs and may have a CT or other radiologic studies (if necessary)
- Patients will have at least yearly evaluations. Patients may be asked for more frequent follow-up depending on their condition and treatment
- Recommendations may be made to the referring physician for alternative treatment options
Additional Information:
- This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
- There is no charge for medical care received at NIH Clinical Center.
- PDQ (Physicians Data Query) - provides additional details about this study for health care providers.
Reviewed: 12/4/08
Updated: 8/9/06
Back to Top
